Researchers have identified a surprising mechanism that helps the toxic Tau protein spread throughout the brain in Alzheimer's disease, potentially paving the way for new therapeutic strategies.
Alzheimer's is characterized by the accumulation of Tau protein, which damages and kills brain cells. As this protein moves to new brain regions, the disease progresses, leading to worsened memory loss and cognitive decline. A recent study in mice has revealed that a brain protein called Arc, usually involved in neuron communication, also appears to facilitate the spread of toxic Tau from diseased to healthy cells.
The findings suggest that future treatments might focus on preventing Tau from reaching healthy brain cells, rather than solely attempting to eliminate it. "I'm excited by the fact that we've identified a new way of potentially stopping the progression of Alzheimer's disease," stated Jason Shepherd, PhD, a professor of neurobiology at the University of Utah Health and senior author of the study, published in the journal Cell.
To understand how Alzheimer's spreads, scientists compared mice with and without the Arc protein. Their experiments showed Arc is crucial for transferring toxic Tau between neurons. Normally, Arc packages itself and important cellular signals into tiny sacs called extracellular vesicles (EVs) that travel between neurons. Toxic Tau appears to hijack this system, attaching to Arc within these vesicles to move from unhealthy to healthy neurons, where it can initiate further damage.
In Alzheimer's, Tau proteins clump into large tangles that disrupt a neuron's internal transport system, eventually leading to cell death. These tangles can break down into smaller "Tau seeds" that are then transferred to new neurons. Once inside a healthy neuron, these seeds corrupt healthy Tau, restarting the disease process. The researchers observed EVs containing both Arc and "sticky" Tau in mouse brain tissue, which were capable of infecting healthy cells and triggering new tangle formation. Removing Arc drastically reduced Tau transfer and disease spread.
Interestingly, Arc also plays a protective role in the early stages by helping neurons expel excess Tau, allowing damaged cells to survive longer. Without Arc, Tau gets trapped, causing cells to die more rapidly. This suggests that blocking EVs from entering healthy neurons, rather than just preventing Tau release, might be a more effective treatment approach.
The study also found EVs containing Arc and Tau in human brain tissue, indicating this mechanism could be present in people. However, researchers emphasize that extensive further research is necessary before any therapies can be developed. "We have some clues that whatever is happening in these mice could also be happening in humans, but we don't know that yet," Shepherd noted. Targeting these specific Tau-containing EVs could offer a way to slow or prevent further cognitive decline and brain damage in individuals with Alzheimer's.
